37 results on '"Spuler S"'
Search Results
2. LGMD
3. FROM THE SPINAL CORD TO THE MUSCLE
4. P.289Precise gene editing of LGMD2A causing mutations
5. P.183Functional progression in dysferlinopathy: results of a 3-year natural history study
6. P.188The clinical outcome study for dysferlinopathy: pregnancy in dysferlinopathy
7. O.19PAX7 deficiency causes mild congenital myopathy with rigid spine and respiratory insufficiency
8. P.177Measuring what matters in dysferlinopathy – linking functional ability to patient reported outcome measures
9. GENE EDITING AND MOLECULAR THERAPY
10. LGMD: EP.182 Quality of life in dysferlinopathy can be good despite poor function
11. LIMB-GIRDLE MUSCULAR DYSTROPHY I
12. LIMB-GIRDLE MUSCULAR DYSTROPHY I
13. LIMB-GIRDLE MUSCULAR DYSTROPHY I
14. Is cardiac dysfunction a feature of dysferlinopathy? Data from the Clinical Outcome Study of Dysferlinopathy
15. Clinical Outcome Study of Dysferlinopathy: what are the best outcome measures for dysferlinopathy patients?
16. Development of primary human satellite cells into an advanced therapeutic medicinal product (ATMP)
17. Is cardiac dysfunction a feature of dysferlinopathy? Data from the clinical outcome study of dysferlinopathy
18. Clinical outcome study of dysferlinopathy: what are the best outcome measures for dysferlinopathy patients?
19. High fat infiltration and increased muscle T2 measured by 1H-NMR in a new dysferlinopathy murine model
20. P.160 - Is cardiac dysfunction a feature of dysferlinopathy? Data from the clinical outcome study of dysferlinopathy
21. G.P.63
22. G.P.284
23. P.41 - High fat infiltration and increased muscle T2 measured by 1H-NMR in a new dysferlinopathy murine model
24. P5.60 Does vitamin D deficiency support myalgia?
25. P2.55 Mstn/Dysf double knockout mice gain muscle mass but no strength
26. P5.67 Electrical muscle stimulation in early severe critical illness prevents type 2 fiber atrophy
27. P3.27 The amazing regenerative potency of human satellite cells - analysis in single fibers
28. P3.16 Myostatin inhibits differentiation of normal and dysferlin-deficient human skeletal myoblasts – similarities and differences
29. P1.18 Dysferlin peptides elicit functional recovery in dysferlin deficient muscular dystrophy
30. P1.53 GLUT4 expression in early critical illness myopathy
31. P1.32 A genetic variant within caveolin-3 protects against statin-induced myopathy
32. G.P.10.04 Is complement inhibition a potential therapy in dysferlin-deficient muscular dystrophy?
33. G.P.284: Dysferlinopathy caused by protein misfolding: The novel murine animal model Dysf-MMex38
34. G.P.63: Identification of widespread alterations of RNA metabolism in sporadic inclusion-body myositis using SILAC-based quantitative proteomics
35. P.389 - Development of primary human satellite cells into an advanced therapeutic medicinal product (ATMP).
36. 222P Development of a standardized information model for rare neuromuscular diseases.
37. P.437 - Clinical outcome study of dysferlinopathy: what are the best outcome measures for dysferlinopathy patients?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.